hr

Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Top
Topic: Ongoing Debate of Entecavir vs. Tenofovir on Reducing the Risk of HCC in Patients with Chronic Hepatitis B

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 30 Nov 2021

Guest Editor(s)

  • Grace Lai-Hung Wong, MD
    Chinese University of Hong Kong, Shatin, Hong Kong, China.

    Website | E-mail

  • Vincent Wai-Sun Wong, MD
    Chinese University of Hong Kong, Shatin, Hong Kong, China.

    Website | E-mail

  • Terry Cheuk Fung Yip, PhD
    Chinese University of Hong Kong, Shatin, Hong Kong, China.

    Website | E-mail

Special Issue Introduction


Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are now equally recommended by all international clinical guidelines as the first-line oral antiviral treatment of patients with chronic hepatitis B. Both ETV and TDF are potent nucleos(t)ide analogues with a high genetic barrier to drug resistance. The majority of patients under long-term potent nucleos(t)ide analogue treatment can achieve hepatitis B virus DNA suppression, which is associated with reduction of disease progression and development of hepatocellular carcinoma (HCC). However, in recent two years, there has been an ongoing debate on the potential differences in effectiveness of ETV and TDF on preventing HCC development. In this special issue of Hepatoma Research, we will give a thorough review on all relevant studies and meta-analyses, as well as look into the difference in methodology and statistical analyses aiming to provide a better understanding of how to interpret the findings in these observational studies and meta-analyses of observational studies. We have split the topic into several sub-topics, as follows:
1. Use of tenofovir disoproxil fumarate is associated with a lower risk of hepatocellular carcinoma than entecavir in patients with chronic hepatitis B;
2. Use of tenofovir disoproxil fumarate is not associated with a lower risk of hepatocellular carcinoma than entecavir in patients with chronic hepatitis B;
3. Overview of methodology and statistical strategies in observational study and meta-analysis;
4. Possible biological mechanisms and impact of ethnicity on entecavir vs. tenofovir disoproxil fumarate on reducing the risk of HCC.

Participants

1. Prof. Jonggi Choi  Department of Gastroenterology Asan Medical Center University of Ulsan College of Medicine 88 Olympic-ro 43-gil, 05505, Songpa-gu, Seoul, Korea.
2. Prof. Seung Up Kim  Department of Internal Medicine, Yonsei University College of Medicine 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.
3. Prof. Hye Won Lee  Department of Internal Medicine, Yonsei University College of Medicine 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.
4. Prof. Kazumoto Murata  Division of Virology, Department of Infection and immunity Jichi Medical University.
5. Prof. Masashi Mizokami  Genome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Japan.
The list is arranged in no particular order and being updated.

Submission Deadline

30 Nov 2021

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=hr&SpecialIssueId=646
Submission Deadline: 30 Nov 2021
Contacts: Ada Zhong, Assistant Editor, editor_Ada@hrjournal.net

Published Articles

This special issue is now open for submission.
© 2016-2021 OAE Publishing Inc., except certain content provided by third parties